Gemcitabine plus Cisplatin versus Gemcitabine plus Carboplatin as First-Line Chemotherapy in Advanced Transitional Cell Carcinoma of the Urothelium: Results of a Randomized Phase 2 Trial

European Urology

Volumn 52, Issue 1, 2007, Pages 134-141

  Dogliotti, Luigi ^a   Cartenì, Giacomo ^b   Siena, Salvatore ^c   Bertetto, Oscar ^d   Martoni, Andrea ^e   Bono, Aldo ^f   Amadori, Dino ^g   Onat, Haluk ^h   Marini, Luca ⁱ  

^a UNIVERSITY OF TURIN   (Italy)

^b CARDARELLI HOSPITAL   (Italy)

^c OSPEDALE NIGUARDA CA GRANDA   (Italy)

^d MOLINETTE HOSPITAL   (Italy)

^e UNIVERSITY OF BOLOGNA   (Italy)

^f Fondazione Macchi   (Italy)

^g MORGAGNI PIERANTONI HOSPITAL   (Italy)

^h Oncology Institute   (Turkey)

ⁱ Div Med Gen   (Italy)

Author keywords

Bladder cancer; Carboplatin; Chemotherapy; Cisplatin; Gemcitabine

Indexed keywords

CARBOPLATIN; CISPLATIN; GEMCITABINE;

ACUTE KIDNEY FAILURE; ADULT; ADVANCED CANCER; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER LOCALIZATION; CANCER SURVIVAL; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; INFECTION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; OTOTOXICITY; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIMARY HEALTH CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; TRANSITIONAL CELL CARCINOMA; TREATMENT RESPONSE; URINARY TRACT CARCINOMA; UROTHELIUM CARCINOMA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, TRANSITIONAL CELL; CISPLATIN; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; ITALY; MALE; MIDDLE AGED; NEOPLASM STAGING; RETROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME; TURKEY; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 34249083806     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2006.12.029     Document Type: Article

References (30)

1. Jemal A., Murray T., Samuels A., et al. Cancer statistics, 2003. CA Cancer J Clin 53 (2003) 5-26
2. Harker W.G., Meyers F.J., Freiha F.S., et al. Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group Study. J Clin Oncol 3 (1985) 1463-1470
3. Sternberg C.N., Yagoda A., Scher H.I., et al. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium. J Urol 139 (1988) 461-469
4. Hillcoat B.L., Raghavan D., Matthews J., et al. A randomized trial of cisplatin versus cisplatin plus methotrexate in advanced cancer of the urothelial tract. J Clin Oncol 7 (1989) 706-709
5. Tannock I., Gospodarowicz M., Connolly J., et al. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) chemotherapy for transitional cell carcinoma: the Princess Margaret Hospital experience. J Urol 142 (1989) 289-292
6. Logothetis C.J., Dexeus F.H., Finn L., et al. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 8 (1990) 1050-1055
7. Loehrer Sr. P.J., Einhorn L.H., Elson P.J., et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 10 (1992) 1066-1073
8. Gatzemeier U., Shepherd F.A., Le Chevalier T., et al. Activity of gemcitabine in patients with non-small cell lung cancer: a multicentre, extended phase II study. Eur J Cancer 32A (1996) 243-248
9. Moore M. Activity of gemcitabine in patients with advanced pancreatic carcinoma. A review. Cancer 78 3 suppl (1996) 633-638
10. Shapiro J.D., Millward M.J., Rischin D., et al. Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel. Gynecol Oncol 63 (1996) 89-93
11. Stadler W.M., Kuzel T., Roth B., et al. Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J Clin Oncol 15 (1997) 3394-3398
12. Sternberg C.N. Gemcitabine in bladder cancer. Semin Oncol 27 1 suppl 2 (2000) 31-39
13. Peters G.J., Bergman A.M., Ruiz van Haperen V.W., et al. Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin Oncol 22 4 suppl 11 (1995) 72-79
14. Mancarella S., Lorusso V., and Manzione L. Gemcitabine/cisplatin in advanced transitional cell carcinoma of the urinary tract (TCC): a phase II multicenter trial. Eur J Cancer 35 suppl 4 (1999) S347 (abstract no. 1405)
15. Moore M.J., Winquist E.W., Murray N., et al. Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 17 (1999) 2876-2881
16. von der Maase H., Andersen L., Crino L., et al. Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: a phase II clinical trial. Ann Oncol 10 (1999) 1461-1465
17. Kaufman D., Raghavan D., Carducci M., et al. Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. J Clin Oncol 18 (2000) 1921-1927
18. von der Maase H., Sengelov L., Roberts J.T., et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 23 (2005) 4602-4608
19. Bamias A., Moulopoulos L.A., Koutras A., et al. The combination of gemcitabine and carboplatin as first-line treatment in patients with advanced urothelial carcinoma. A Phase II study of the Hellenic Cooperative Oncology Group. Cancer 106 (2006) 297-303
20. Linardou H., Aravantinos G., Efstathiou E., et al. Gemcitabine and carboplatin combination as first-line treatment in elderly patients and those unfit for cisplatin-based chemotherapy with advanced bladder carcinoma: phase II study of the Hellenic Co-operative Oncology Group. Urology 64 (2004) 479-484
21. Van Echo D.A., Egorin M.J., and Aisner J. The pharmacology of carboplatin. Semin Oncol 16 2 suppl 5 (1989) 1-6
22. Kaplan E.L., and Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 53 (1958) 457-481
23. Calvert A.H., Newell D.R., Gumbrell L.A., et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7 (1989) 1748-1756
24. Cockcroft D.W., and Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 16 (1976) 31-41
25. Edelman MJ, Gandara DR, Lau D. Carboplatin (CBDCA)/gemcitabine (GEM) in NSCLC: interim analysis of a novel 21 day schedule. Chemotherapy of non-small cell lung cancer: ten years later. Perugia International Cancer Conference VI, Perugia, Italy. 1998;6:105.
26. Rinaldi M., Crino L., Scagliotti G.V., et al. A three-week schedule of gemcitabine-cisplatin in advanced non-small-cell lung cancer with two different cisplatin dose levels: a phase II randomized trial. Ann Oncol 11 (2000) 1295-1300
27. Carles J., Nogue M., Doménech M., et al. Carboplatin-gemcitabine treatment of patients with transitional cell carcinoma of the bladder and impaired renal function. Oncology 59 (2000) 24-27
28. Bellmunt J., de Wit R., Albanell J., et al. A feasibility study of carboplatin with fixed dose of gemcitabine in "unfit" patients with advanced bladder cancer. Eur J Cancer 37 (2001) 2212-2215
29. Shannon C., Crombie C., Brooks A., et al. Carboplatin and gemcitabine in metastatic transitional cell carcinoma of the urothelium: effective treatment of patients with poor prognostic features. Ann Oncol 12 (2001) 947-952
30. Nogue-Aliguer M., Carles J., Arrivi A., et al., for the Spanish Cooperative Group. Gemcitabine and carboplatin in advanced transitional cell carcinoma of the urinary tract: an alternative therapy. Cancer 97 (2003) 2180-2186